Edition:
United States

Foamix Pharmaceuticals Ltd (FOMX.OQ)

FOMX.OQ on NASDAQ Stock Exchange Global Market

5.91USD
12:38pm EDT
Change (% chg)

$0.00 (+0.00%)
Prev Close
$5.91
Open
$5.91
Day's High
$6.07
Day's Low
$5.66
Volume
81,114
Avg. Vol
96,019
52-wk High
$7.55
52-wk Low
$4.45

Latest Key Developments (Source: Significant Developments)

Foamix Announces Positive Topline Results From Third Phase 3 Trial Evaluating FMX101 For Moderate-To-Severe Acne
Tuesday, 11 Sep 2018 05:00pm EDT 

Sept 11 (Reuters) - Foamix Pharmaceuticals Ltd ::FOAMIX ANNOUNCES POSITIVE TOPLINE RESULTS FROM THIRD PHASE 3 TRIAL (STUDY FX2017-22) EVALUATING FMX101 TOPICAL MINOCYCLINE FOAM FOR MODERATE-TO-SEVERE ACNE.FOAMIX PHARMACEUTICALS LTD - SAFETY PROFILE OF FMX101 WAS FOUND TO BE CONSISTENT WITH THAT DETERMINED FROM TWO PRIOR PHASE 3 STUDIES.FOAMIX PHARMACEUTICALS - FMX101 DEMONSTRATED HIGHLY STATISTICALLY SIGNIFICANT IMPROVEMENT COMPARED WITH VEHICLE IN BOTH CO-PRIMARY EFFICACY ENDPOINTS.FOAMIX PHARMACEUTICALS LTD - PLANS TO CONTINUE TO SHARE DATA FROM THIS STUDY AS THEY BECOME AVAILABLE OVER REMAINDER OF 2018.FOAMIX PHARMACEUTICALS LTD - STUDY MET BOTH CO-PRIMARY ENDPOINTS OF ABSOLUTE CHANGE FROM BASELINE IN INFLAMMATORY LESION COUNT AT WEEK 12.FOAMIX PHARMACEUTICALS LTD - STUDY ALSO MET CO-PRIMARY ENDPOINTS OF INVESTIGATOR GLOBAL ASSESSMENT TREATMENT SUCCESS AT WEEK 12.  Full Article

Foamix Announces Dosing Of Last Patient In Phase 3 Rosacea Studies For Minocycline Foam Fmx103
Wednesday, 27 Jun 2018 08:00am EDT 

June 27 (Reuters) - Foamix Pharmaceuticals Ltd ::FOAMIX ANNOUNCES DOSING OF LAST PATIENT IN PHASE 3 ROSACEA STUDIES FOR MINOCYCLINE FOAM FMX103.FOAMIX PHARMACEUTICALS - TWO PHASE 3 PIVOTAL STUDIES ARE BEING RUN SIMULTANEOUSLY, CURRENTLY ANTICIPATES TOP-LINE RESULTS EARLY IN Q4 OF THIS YEAR.  Full Article

Foamix Reports Fiscal Year 2017 Financial Results And Provides Corporate Update
Wednesday, 28 Feb 2018 08:00am EST 

Feb 28 (Reuters) - Foamix Pharmaceuticals Ltd ::FOAMIX REPORTS FISCAL YEAR 2017 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE.FOAMIX PHARMACEUTICALS LTD - AT DECEMBER 31, 2017, HAD $76.4 MILLION IN CASH AND INVESTMENTS COMPARED TO $131 MILLION AT END OF DECEMBER 2016.  Full Article

Tamarkin Medical Reports 7.3 Percent Passive Stake In Foamix Pharmaceuticals
Tuesday, 13 Feb 2018 05:20pm EST 

Feb 13 (Reuters) - Foamix Pharmaceuticals Ltd ::TAMARKIN MEDICAL INNOVATIONS LTD REPORTS 7.3 PERCENT PASSIVE STAKE IN FOAMIX PHARMACEUTICALS AS OF DECEMBER 31, 2017 - SEC FILING.  Full Article

Foamix Q2 loss per share $0.44
Tuesday, 8 Aug 2017 04:01pm EDT 

Aug 8 (Reuters) - Foamix Pharmaceuticals Ltd :Foamix reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.44.Q2 revenue $798,000 versus $752,000.Foamix pharmaceuticals - ‍"currently well-capitalized", have sufficient cash to fund key development programs (FMX101 and FMX103) until mid-2019​.  Full Article

Foamix says expects to report top-line results from study FX2017-22 by mid-2018​
Thursday, 3 Aug 2017 08:00am EDT 

Aug 3 (Reuters) - Foamix Pharmaceuticals Ltd :Foamix announces dosing of first patient in third phase 3 acne study for minocycline foam fmx101.Foamix pharmaceuticals ltd- ‍foamix expects to report top-line results from study fx2017-22 by mid-2018​.Foamix pharmaceuticals - ‍as result of fda discussion on design of third study, co decided to maintain design agreed upon with fda for study fx2014-05​.  Full Article

Foamix Pharmaceuticals appoints David Domzalski as CEO
Thursday, 29 Jun 2017 08:00am EDT 

June 29 (Reuters) - Foamix Pharmaceuticals Ltd ::Foamix Pharmaceuticals appoints David Domzalski as chief executive officer.Foamix Pharmaceuticals Ltd - Domzalski succeeds Dov Tamarkin as CEO.Foamix Pharmaceuticals Ltd - Tamarkin will continue to be a member of company's Board of directors and will serve as chief scientific advisor to Foamix.Foamix Pharmaceuticals Ltd - Ilan Hadar, current CFO of Foamix, will assume role of country manager in Israel, in addition to his role as CFO.  Full Article

Foamix announces dosing of first patient in phase 3 rosacea clinical trials
Monday, 12 Jun 2017 08:00am EDT 

June 12 (Reuters) - Foamix Pharmaceuticals Ltd :Foamix announces dosing of first patient in phase 3 rosacea clinical trials for FMX103 minocycline foam 1.5%.Foamix Pharmaceuticals Ltd - "we expect topline data in mid-2018".  Full Article

Foamix Pharmaceuticals reports Q1 2017 financial results
Tuesday, 9 May 2017 04:05pm EDT 

May 9 (Reuters) - Foamix Pharmaceuticals Ltd ::Foamix reports first quarter 2017 financial results and provides business update.Q1 loss per share $0.39.Q1 revenue $927,000 versus $745,000.Says as of march 31, 2017, we had cash and investments of $118.7 million, compared with $131.0 million as of december 31, 2016.  Full Article

Foamix Pharmaceuticals announces plans for additional phase 3 trial for FMX101 in moderate to severe acne
Monday, 1 May 2017 04:05pm EDT 

May 1 (Reuters) - Foamix Pharmaceuticals Ltd ::Foamix Pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne.Foamix Pharmaceuticals ltd- commencement of 3(rd) phase 3 trial planned mid 2017; submittal of nda planned in h2-2018.Foamix pharmaceuticals announces plans for additional phase 3 trial for fmx101 in moderate to severe acne.Foamix pharmaceuticals ltd- pooled analyses of phase 3 data show additional statistically significant effects on primary and secondary efficacy endpoints.Foamix pharmaceuticals - if results will be positive, trial is expected to form basis for a nda which company plans to submit in second half of 2018.  Full Article

Foamix acne drug meets main goals in late-stage trial, shares surge

Foamix Pharmaceuticals Ltd said on Tuesday that its lead drug treating moderate-to-severe acne met the main goals of its third late-stage study, sending its shares up 57 percent in extended trading.